Literature DB >> 31477192

Clinical characterisation of a novel SCN5A variant associated with progressive malignant arrhythmia and dilated cardiomyopathy.

Adam C Kean1, Benjamin M Helm2,3, Matteo Vatta2,4, Mark D Ayers1, John J Parent5, Robert K Darragh5.   

Abstract

INTRODUCTION: The SCN5A gene is implicated in many arrhythmogenic and cardiomyopathic processes. We identified a novel SCN5A variant in a family with significant segregation in individuals affected with progressive sinus and atrioventricular nodal disease, atrial arrhythmia, dilated cardiomyopathy, and early sudden cardiac arrest.
METHODS: A patient pedigree was created following the clinical evaluation of three affected individuals, two monozygotic twins and a paternal half-brother, which lead to the evaluation of a paternal half-sister (four siblings with the same father and three mothers) all of whom experienced varying degrees of atrial arrhythmias, conduction disease, and dilated cardiomyopathy in addition to a paternal history of unexplained death in his 50s with similar autopsy findings. The index male underwent sequencing of 58 genes associated with cardiomyopathies. Sanger sequencing was used to provide data for bases with insufficient coverage and for bases in some known regions of genomic segmental duplications. All clinically significant and novel variants were confirmed by independent Sanger sequencing.
RESULTS: All relatives tested were shown to have the same SCN5A variant of unknown significance (p. Asp197His) and the monozygotic twins shared a co-occurring NEXN (p. Glu575*). Segregation analysis demonstrates likely pathogenic trait for the SCN5A variant with an additional possible role for the NEXN variant in combination.
CONCLUSIONS: There is compelling clinical evidence suggesting that the SCN5A variant p. Asp197His may be re-classified as likely pathogenic based on the segregation analysis of our family of interest. Molecular mechanism studies are pending.

Entities:  

Keywords:  SCN5A; dilated cardiomyopathy; sudden cardiac arrest

Mesh:

Substances:

Year:  2019        PMID: 31477192     DOI: 10.1017/S1047951119001860

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  2 in total

1.  Loss of Nexilin function leads to a recessive lethal fetal cardiomyopathy characterized by cardiomegaly and endocardial fibroelastosis.

Authors:  Josefin Johansson; Carina Frykholm; Katharina Ericson; Kalliopi Kazamia; Amanda Lindberg; Nancy Mulaiese; Geir Falck; Per-Erik Gustafsson; Sarah Lidéus; Sanna Gudmundsson; Adam Ameur; Marie-Louise Bondeson; Maria Wilbe
Journal:  Am J Med Genet A       Date:  2022-02-15       Impact factor: 2.578

Review 2.  Childhood onset nexilin dilated cardiomyopathy: A heterozygous and a homozygous case.

Authors:  Luc Bruyndonckx; Judith L Vogelzang; Marianna Bugiani; Bart Straver; Irene M Kuipers; Wes Onland; Eline A Nannenberg; Sally-Ann Clur; Saskia N van der Crabben
Journal:  Am J Med Genet A       Date:  2021-05-05       Impact factor: 2.802

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.